{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408925000
| IUPAC_name = (5''R'',5a''R'',8a''R'',9''S'')-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-({4,6-''O''-[(''R'')-2-thienylmethylene]-β-<small>D</small>-glucopyranosyl}oxy)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5a''H'')-one
| image = Teniposide2DACS.svg
<!--Clinical data-->
| tradename = Vumon
| Drugs.com = {{drugs.com|monograph|teniposide}}
| MedlinePlus = a692045
| pregnancy_AU = D
| pregnancy_US = D
| legal_US = Rx-only
| routes_of_administration = [[Intravenous therapy|Intravenous]]
<!--Pharmacokinetic data-->
| bioavailability = N/A
| protein_bound = >99%
| metabolism = [[Liver|Hepatic]] ([[CYP2C19]]-mediated)
| elimination_half-life = 5 hours
| excretion = [[Kidney|Renal]] and fecal
<!--Identifiers-->
| IUPHAR_ligand = 6843
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 29767-20-2
| ATC_prefix = L01
| ATC_suffix = CB02
| PubChem = 34698
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00444
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 31930
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 957E6438QA
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 75988
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02698
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200536
| synonyms = VM-26
<!--Chemical data-->
| C=32 | H=32 | O=13 | S=1
| molecular_weight = 656.655 g/mol
| smiles = COc1cc(cc(c1O)OC)[C@@H]2c3cc4c(cc3[C@H]([C@@H]5[C@@H]2C(=O)OC5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)c8cccs8)O)O)OCO4
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31?,32-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = NRUKOCRGYNPUPR-PSZSYXFXSA-N
}}
'''Teniposide''' (trade name '''Vumon''') is a [[chemotherapy|chemotherapeutic]] [[medication]]<ref>{{cite journal|doi=10.1016/j.jep.2005.05.011|title=Plants as a source of anti-cancer agents|year=2005|last1=Cragg|first1=Gordon M.|last2=Newman|first2=David J.|journal=Journal of Ethnopharmacology|volume=100|pages=72–9|pmid=16009521|issue=1–2}}</ref> used in the treatment of childhood [[acute lymphocytic leukemia]] (ALL), [[Hodgkin's lymphoma]], certain [[brain tumour]]s, and other types of cancer.<ref name="Austria-Codex">{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=62nd|pages=8855–6|isbn=978-3-85200-181-4|language=German}}</ref> It is in a class of drugs known as [[podophyllotoxin]] derivatives and slows the growth of [[cancer]] cells in the body.<ref name="Drugs.com">Drugs.com: Teniposide {{drugs.com|monograph|teniposide}}.</ref>

==Medical uses==
Teniposide is used for the treatment of a number of cancer types in children. In the US, it is approved for the second-line therapy of acute lymphocytic leukemia (ALL) in combination with other [[antineoplastic]] drugs.<ref name="Drugs.com" /> In Europe, it is also approved for the treatment of Hodgkin's lymphoma, generalized [[malignant lymphoma]], [[reticulocyte]] [[sarcoma]], acute [[leukaemia]], primary brain tumours ([[glioblastoma]], [[ependymoma]], [[astrocytoma]]), [[bladder cancer]], [[neuroblastoma]] and other solid tumours in children.<ref name="Austria-Codex" />

===Administration===
The medication is [[Intravenous therapy|injected though a vein]] and burns if it leaks under the skin. It can be used in combination with other anticancer drugs.<ref name="Austria-Codex" />

==Contraindiactions==
The drug is contraindicated during pregnancy and [[lactation]], in patients with severe liver or kidney impairment or severely impaired [[haematopoiesis]].<ref name="Austria-Codex" />

==Side effects==
Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe [[bone marrow suppression]]. Other common side effects include [[gastrointestinal]] toxicity, [[hypersensitivity]] reactions, and reversible [[alopecia]].<ref name="Austria-Codex" />

==Interactions==
No systematic interaction studies are available. The [[enzyme inducer]]s [[phenobarbital]] and [[phenytoin]] have been found to lower its blood plasma concentrations.<ref name="Mutschler" /> Theoretically possible interactions include increased plasma concentrations when combined with [[sodium salicylate]], [[sulfamethizole]] or [[tolbutamide]], which displace teniposide from [[plasma protein binding]], at least ''[[in vitro]]''.<ref name="Austria-Codex" /><ref name="Drugs.com" />

==Pharmacology==

===Mechanism of action===
Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA-protein cross-links.<ref name="Austria-Codex" /> The substance has been found to act as an [[topoisomerase II inhibitor|inhibitor of topoisomerase II]] (an enzyme that aids in DNA unwinding),<ref name="Mutschler">{{Cite book|last1=Mutschler|first1=Ernst|last2=Schäfer-Korting|first2=Monika|title=Arzneimittelwirkungen|language=German|location=Stuttgart|publisher=Wissenschaftliche Verlagsgesellschaft|year=2001|edition=8|pages=894–5|isbn=3-8047-1763-2}}</ref><ref>{{cite journal|pmid=8382551|year=1993|author1=De Jong|first1=S|title=Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells|journal=Cancer research|volume=53|issue=5|pages=1064–71|last2=Kooistra|first2=A. J.|last3=De Vries|first3=E. G.|last4=Mulder|first4=N. H.|last5=Zijlstra|first5=J. G.}}</ref> since it does not intercalate into DNA or bind strongly to DNA. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.{{citation needed|date=November 2015}}

==Chemistry==
[[File:Podophyllum peltatum - Köhler–s Medizinal-Pflanzen-246.jpg|thumb|left|An illustration of the [[wild mandrake]], showing part of the [[rhizome]] (at bottom)]]
Teniposide is a [[semisynthetic]] derivative of [[podophyllotoxin]]<ref name="Austria-Codex" /> from the [[rhizome]] of the [[wild mandrake]] (''Podophyllum peltatum''). More specifically, it is a [[glycoside]] of podophyllotoxin with a <small>D</small>-[[glucose]] derivative. It is chemically similar to the anti-cancer drug [[etoposide]], being distinguished only by a [[thienyl]] rest where etoposide has a methyl.<ref name="Mutschler" /> Both these compounds have been developed with the aim of creating less toxic derivatives of podophyllotoxin.<ref>{{cite book|title=Arzneistoff-Profile|editor=Dinnendahl, V |editor2=Fricke, U|publisher=Govi Pharmazeutischer Verlag|location=Eschborn, Germany|date=2015|edition=28|volume=4|isbn=978-3-7741-9846-3|language=German}}</ref>

==References==
{{Reflist|35em}}

{{Chemotherapeutic agents}}

[[Category:Topoisomerase inhibitors]]
[[Category:IARC Group 2A carcinogens]]
[[Category:Thiophenes]]
[[Category:Phenol ethers]]
[[Category:Furonaphthodioxoles]]
[[Category:Phenols]]